| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 49 companies in the Life Sciences Tools & Services industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2019 | CRL Charles River Laboratories International, Inc. | Foster James C77 | Chairman, President And CEO | Sell | 3,957 | $140.55 | $556,159.17 | - | |
| Feb 27, 2019 | DHR Danaher Corp /de/ | Ellis Brian W62 | Senior Vice President - GC | Sell | 1,564 | $127.22 | $198,976.77 | -6.9% | |
| Feb 27, 2019 | DHR Danaher Corp /de/ | Comas Daniel L | EVP | Sell | 97,357 | $127.04 | $12,368,002.76 | -26.6% | |
| Feb 27, 2019 | DHR Danaher Corp /de/ | Raskas Daniel67 | Svp-corporate Development | Sell | 49,164 | $126.45 | $6,216,661.50 | -48.7% | |
| Feb 27, 2019 | CRL Charles River Laboratories International, Inc. | Foster James C77 | Chairman, President And CEO | Sell | 4,374 | $140.84 | $616,018.70 | - | |
| Feb 27, 2019 | CRL Charles River Laboratories International, Inc. | Barbo William D66 | Corporate Executive VP &CCO | Sell | 11,222 | $140.69 | $1,578,851.85 | -1.0% | |
| Feb 27, 2019 | CRL Charles River Laboratories International, Inc. | Barbo William D66 | Corporate Executive VP &CCO | Sell | 8,155 | $141.03 | $1,150,071.88 | -1.1% | |
| Feb 27, 2019 | NOTV Inotiv, Inc. | Oakley Daniel Thomas | Chief Operating Officer | Buy | 10,826 | $1.53 | $16,563.78 | New | |
| Feb 27, 2019 | CRL Charles River Laboratories International, Inc. | Barbo William D66 | Corporate Executive VP &CCO | Sell | 5,324 | $140.48 | $747,921.11 | -0.5% | |
| Feb 27, 2019 | NEO Neogenomics Inc | Jones Steven C | Executive Vice President | Sell | 299,873 | $18.90 | $5,668,743.32 | -6.3% | |
| Feb 27, 2019 | NEO Neogenomics Inc | Shovlin Robert J. | President, Clinical Services | Sell | 186,014 | $18.96 | $3,527,391.57 | -39.0% | |
| Feb 27, 2019 | EXAS Exact Sciences Corp | Coward D Scott77 | Chief Administrative Officer | Sell | 9,803 | $95.07 | $932,010.42 | -9.2% | |
| Feb 27, 2019 | EXAS Exact Sciences Corp | Conroy Kevin T81 | President And CEO | Sell | 9,169 | $95.07 | $871,733.51 | -1.0% | |
| Feb 26, 2019 | CRL Charles River Laboratories International, Inc. | Smith David Ross63 | Corporate Executive VP &CFO | Sell | 1,587 | $141.51 | $224,579.43 | -0.5% | |
| Feb 26, 2019 | NEO Neogenomics Inc | Hipp Raymond R | Director | Sell | 18,889 | $18.90 | $357,002.10 | -6.2% | |
| Feb 26, 2019 | CRL Charles River Laboratories International, Inc. | Foster James C77 | Chairman, President And CEO | Sell | 3,499 | $139.94 | $489,647.78 | - | |
| Feb 26, 2019 | CRL Charles River Laboratories International, Inc. | Smith David Ross63 | Corporate Executive VP &CFO | Sell | 4,050 | $139.76 | $566,014.80 | -0.6% | |
| Feb 26, 2019 | WAT Waters Corp /de/ | Glimcher Laurie H M.D. | Director | Sell | 1,485 | $238.69 | $354,454.65 | -20.4% | |
| Feb 26, 2019 | CRL Charles River Laboratories International, Inc. | Foster James C77 | Chairman, President And CEO | Sell | 1,630 | $143.71 | $234,249.95 | - | |
| Feb 26, 2019 | CRL Charles River Laboratories International, Inc. | Foster James C77 | Chairman, President And CEO | Sell | 4,135 | $139.52 | $576,904.56 | - | |
| Feb 26, 2019 | CRL Charles River Laboratories International, Inc. | Foster James C77 | Chairman, President And CEO | Sell | 3,756 | $141.75 | $532,396.36 | - | |
| Feb 26, 2019 | CRL Charles River Laboratories International, Inc. | Foster James C77 | Chairman, President And CEO | Sell | 5,072 | $139.72 | $708,658.64 | - | |
| Feb 26, 2019 | CRL Charles River Laboratories International, Inc. | Foster James C77 | Chairman, President And CEO | Sell | 3,673 | $140.25 | $515,130.98 | - | |
| Feb 26, 2019 | NEO Neogenomics Inc | Bonello William | Chief Strategy Officer | Sell | 60,203 | $18.90 | $1,137,836.70 | -100% | |
| Feb 26, 2019 | VCYT Veracyte, Inc. | Anderson Bonnie H72 | Chairman And CEO | Sell | 20,000 | $20.94 | $418,729.32 | -11.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.